Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

- Expands Staff to Continue Record of Investment Success -

GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations by adding the therapeutic areas of cardiovascular and metabolic disease, pain and central nervous system disorders and gastrointestinal disease. Traditionally, MedImmune Ventures has focused its efforts on the areas of infectious disease, oncology and inflammatory disease. Since its inception in 2002, MedImmune Ventures has invested in 22 companies.

"We look forward to making meaningful investments in these additional therapeutic areas," said Edward T. Mathers, executive vice president, corporate development and venture, MedImmune. "Now that we are more fully aligned with AstraZeneca's core areas of interest, we are able to help both MedImmune and AstraZeneca to stay at the forefront of novel science with a direct window to the most innovative start-ups in the biotechnology industry."

Mr. Mathers and MedImmune President & CEO David M. Mott currently lead MedImmune Ventures. To accommodate the broader disease area focus, MedImmune Ventures has added Maggie Flanagan LeFlore, Ph.D. and Eva M. Jack as managing directors to its team of experts that oversee the assessment of all new investment opportunities. Previously, Dr. LeFlore was on assignment from AstraZeneca to the healthcare and life science venture investment team at Advent International, and Ms. Jack was director, business development at MedImmune. Also, Joseph L. Amprey, M.D., Ph.D. was promoted to managing director of MedImmune Ventures following the June 2007 retirement of its president, Wayne T. Hockmeyer, Ph.D. Franklin H. Top, M.D., who has been with MedImmune since 1988 and is the company's former m
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... Can economic incentives such as gift cards, ... the public to increase their donations of blood? , ... Business School Assistant Professor Mario Macis says the ... body of recent research that supports their argument, the ... of Science that the World Health Organization and national ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... Increase In Total Revenue To $5.6 Million; 34% Increase ... -- International Isotopes Inc. (OTC Bulletin Board: INIS) ... 31, 2008. Total Revenue . ... in 2007, which represents an increase of $911,885 or ...
... Fla., March 27 Catalyst Pharmaceutical Partners, Inc. ... that acquires, in-licenses, develops and commercializes prescription drugs ... financial results for the fourth quarter and year ... 2008," said Patrick J. McEnany, Chief Executive Officer ...
... sensitivity of Magnetic Resonance techniques including those used in ... scientists at the University of York. , Ultimately, the ... space shuttle, is expected to allow doctors to learn ... scan at lower cost while increasing the range of ...
Cached Biology Technology:International Isotopes Inc. Announces Year End Financial Results 2International Isotopes Inc. Announces Year End Financial Results 3International Isotopes Inc. Announces Year End Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 2Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 3Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 5Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 6Transforming medical diagnosis with new scanning technology 2
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
(Date:5/22/2013)... Trial (NLST) investigators also conclude that the 20 ... computed tomography (LDCT) versus chest X-ray (CXR) screening ... achievable at experienced screening centers in the United ... share with their patients about the benefits and ... publication in the New England Journal of ...
(Date:5/22/2013)... streamlined approach to genetic engineering drastically reduces the ... into bacteria, the workhorses of biotechnology, scientists are ... Biology , the method paves the way for ... development, environmental cleanup and other activities. , Keith ... a piece of the genetic material DNA into ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... , , , , ... AUDIO: Dr Andrew Marshall, from the Environment Department at the University of York, ... Click here for more information. , , , ... , , , , , , ...
... Carlos Mara Romeo Casabona is Director of the Interuniversity Professorship ... the University of the Basque Country. The Professorship is largely ... as researchers in the fields of molecular biology, medicine and ... and the Humane Genome at the Universities of Deusto and ...
... CINCINNATI -- Children exposed prenatally to tobacco smoke and ... ADHD, according to research done at Cincinnati Children,s Hospital Medical ... of ADHD cases in children between the ages of 8 ... environmental exposures. This could translate into up to 800,000 children ...
Cached Biology News:New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research and legislation should go hand in hand, as much as possible 2Exposure to lead, tobacco smoke raises risk of ADHD 2
... The MSD Security ... integrated GC/MS software application ... processing, quantification, library searching ... the aspects of data ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: